Business
InspireMD Announces Successful Live Clinical Case Transmissions Featuring CGuard™ EPS at the Leipzig Interventional Course (LINC) 2020
Case demonstrates ease-of-use and exceptional patient safety features of CGuard™ EPS TEL AVIV, Israel, Jan. 29, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE
About this update from Inspiremd Inc.
[{"type":"text","content":"Case demonstrates ease-of-use and exceptional patient safety features of CGuard™ EPS\nTEL AVIV, Israel, Jan. 29, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, today announced that a successful live case featuring CGuard™ EPS was presented at the international LINC conference 2020, which is being held January 28 – 31 in Leipzig, Germany.\n “For the third year in a row, we were chosen to showcase CGuard™ EPS in a live case procedure. This again confirms both clinical utility and ease of use of the device relative to alternative stent options and carotid endarterectomy,” said Marvin Slosman, chief executive officer of InspireMD. “Together with the panel discussions and presentations featuring CGuard™ EPS at this year’s LINC conference, the totality of evidence demonstrating CGuard’s safety and efficacy continues to reiterate the value of CGuard as a standard of care treatment for carotid artery disease. We would like to express our thanks to Drs. Micari and Castriota, two world-renowned interventionalists, for again demonstrating superior results of CGuard™ EPS in a real-time clinical setting.” Live case #17: Symptomatic high-risk carotid artery disease The live case was conducted by Dr. Antonio Micari and Dr. Fausto Castriota, interventional cardiologists at Humanitas Gavazzeni Hospital, Bergamo, Italy. The 82-year old male patient presented with symptomatic high-risk carotid artery disease and experienced a transient ischemic attack (TIA) with left-sided hemiparesis approximately one month ago. Risk factors included hypertension and hypercholesterolemia. The procedure was successfully performed with CGuard™ EPS, lasted approximately 20 minutes and had an excellent angiographic result. Following the procedure, Drs. Micari and Castriota commented, “We believe CGuard™ EPS is a game changer in the plaque–stent interaction paradigm.” About LINCLINC is a leading global forum for new methods in the field of vascular medicine. LINC brings together medical professionals from different specialties around the world who perform endovascular interventions. About InspireMD, Inc.InspireMD seeks to utilize its proprietary MicroNet® technology to make its products the industry standard for treatment of carotid ...